Researchers Discover Why Tumor Resists Therapy

Armen Hareyan's picture

CLEVELAND - A new study, published in the Feb. 24, 2005, issue of The New England Journal of Medicine, helps to explain why non-small-cell lung cancer (NSCLC) tumors become resistant to the cancer therapy gefitinib (Iressa).

Researchers at Beth Israel Deaconess Medical Center in Boston and the Ireland Cancer Center at University Hospitals of Cleveland say their discovery of a second mutation in a gene already associated with NSCLC could trigger the development of 'inhibitor' drugs to treat NSCLC.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.